Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Abstract Objective To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC tre...

Full description

Bibliographic Details
Main Authors: Timo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, Minal Jain, Janne Martikainen
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Psoriatic arthritis
Cost-effectiveness
Biologics
Secukinumab
Incremental cost effectiveness ratio
Quality adjusted life years
Online Access:http://link.springer.com/article/10.1186/s12962-018-0162-3

Internet

http://link.springer.com/article/10.1186/s12962-018-0162-3

Similar Items